SCHEMBL2371602

SCHEMBL2371602

OCCN1CCN(c2cc(Nc3nccc4nc(-c5c(Cl)cccc5Cl)[nH]c34)ncn2)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 16/20 0.78
JAK2 O60674 14/20 0.78
SRC P12931 4/20 0.48
LCK P06239 3/20 0.48
LYN P07948 3/20 0.48
KDR P35968 2/20 0.48
INSR P06213 1/20 0.48
EPHB6 O15197 2/20 0.38
ABL1 P00519 2/20 0.38
EGFR P00533 2/20 0.38
FYN P06241 2/20 0.38
CSF1R P07333 2/20 0.38
YES1 P07947 2/20 0.38
RET P07949 2/20 0.38
HCK P08631 2/20 0.38
KIT P10721 2/20 0.38
BCR P11274 2/20 0.38
BRAF P15056 2/20 0.38
EPHA1 P21709 2/20 0.38
EPHA2 P29317 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371361 0.94 TYK2 (0.70) TYK2JAK2SRCLCKLYN
SCHEMBL2371499 0.90 TYK2 (0.62) TYK2JAK2ABL1JAK3
SCHEMBL12294740 0.89 TYK2 (0.71) TYK2JAK2SRCLCKLYN
SCHEMBL12295383 0.89 TYK2 (0.70) TYK2JAK2KDRJAK3
SCHEMBL12294719 0.89 TYK2 (0.73) TYK2JAK2JAK3
SCHEMBL2372389 0.88 JAK2 (0.61) TYK2JAK2SRCLCKLYN
SCHEMBL2372584 0.88 TYK2 (0.60) TYK2JAK2SRCLCKLYN
SCHEMBL2371829 0.88 TYK2 (0.72) TYK2JAK2JAK3
SCHEMBL2372075 0.87 JAK2 (0.59) TYK2JAK2SRCLCKLYN
SCHEMBL2372211 0.86 TYK2 (0.75) TYK2JAK2EGFRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
EP-2547338-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2013-01-23 EP disclosed
WO-2011113802-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 WO disclosed
WO-2011113802-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 TYK2 1/4885JAK2 6/4885SRC 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.